Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

538 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Impact of antibiotic stewardship on perioperative antimicrobial prophylaxis.
Murri R, de Belvis AG, Fantoni M, Tanzariello M, Parente P, Marventano S, Bucci S, Giovannenze F, Ricciardi W, Cauda R, Sganga G; collaborative SPES Group. Murri R, et al. Among authors: cauda r. Int J Qual Health Care. 2016 Sep;28(4):502-7. doi: 10.1093/intqhc/mzw055. Epub 2016 Jun 9. Int J Qual Health Care. 2016. PMID: 27283440
Consensus document on controversial issues in the treatment of complicated skin and skin-structure infections.
Pan A, Cauda R, Concia E, Esposito S, Sganga G, Stefani S, Nicastri E, Lauria FN, Carosi G, Moroni M, Ippolito G; GISIG (Gruppo Italiano di Studio sulle Infezioni Gravi) Working Group on Complicated Skin and Skin-Structure Infections. Pan A, et al. Among authors: cauda r. Int J Infect Dis. 2010 Oct;14 Suppl 4:S39-53. doi: 10.1016/j.ijid.2010.05.007. Epub 2010 Sep 20. Int J Infect Dis. 2010. PMID: 20851013 Free article.
Italian guidelines for the use of antiretroviral agents and the diagnostic-clinical management of HIV-1 infected persons.
Antinori A, Marcotullio S, Ammassari A, Andreoni M, Angarano G, Carosi G, Cinque P, d'Arminio Monforte A, Di Perri G, Ensoli B, Ferrazzi E, Galli M, Mastroianni C, Matteelli A, Mazzotta F, Moroni M, Palù G, Puoti M, Puro V, Rizzardini G, Sagnelli E, Suter F, Vella S, Lazzarin A; Italian HIV Guidelines Working Group. Antinori A, et al. New Microbiol. 2011 Apr;34(2):109-46. Epub 2011 Apr 30. New Microbiol. 2011. PMID: 21617825 Free article. No abstract available.
How could we reduce antibiotic use in critically ill patients?
De Angelis G, Restuccia G, Cauda R, Tacconelli E. De Angelis G, et al. Among authors: cauda r. Infect Disord Drug Targets. 2011 Aug;11(4):376-83. doi: 10.2174/187152611796504791. Infect Disord Drug Targets. 2011. PMID: 21679144
Italian guidelines for the use of antiretroviral agents and the diagnostic-clinical management of HIV-1 infected persons. Update 2011.
Antinori A, Marcotullio S, Ammassari A, Andreoni M, Angarano G, Armignacco O, Carosi G, Cinque P, d'Arminio Monforte A, Di Perri G, Ensoli B, Floridia M, Galli M, Mastroianni C, Matteelli A, Mazzotta F, Moroni M, Pal G, Puoti M, Puro V, Rizzardini G, Sagnelli E, Vella S, Vullo V, Lazzarin A; Italian HIV Guidelines Working Group. Antinori A, et al. New Microbiol. 2012 Apr;35(2):113-59. Epub 2012 Mar 31. New Microbiol. 2012. PMID: 22707127 Free article. No abstract available.
Safety and feasibility of treatment simplification to atazanavir/ritonavir + lamivudine in HIV-infected patients on stable treatment with two nucleos(t)ide reverse transcriptase inhibitors + atazanavir/ritonavir with virological suppression (Atazanavir and Lamivudine for treatment Simplification, AtLaS pilot study).
Di Giambenedetto S, Fabbiani M, Colafigli M, Ciccarelli N, Farina S, Sidella L, D'Avino A, Mondi A, Cingolani A, Tamburrini E, Murri R, Navarra P, Cauda R, De Luca A. Di Giambenedetto S, et al. Among authors: cauda r. J Antimicrob Chemother. 2013 Jun;68(6):1364-72. doi: 10.1093/jac/dkt007. Epub 2013 Jan 30. J Antimicrob Chemother. 2013. PMID: 23372058
Safety and efficacy of treatment switch to raltegravir plus tenofovir/emtricitabine or abacavir/lamivudine in patients with optimal virological control: 48-week results from a randomized pilot study (Raltegravir Switch for Toxicity or Adverse Events, RASTA Study).
Fabbiani M, Mondi A, Colafigli M, D'Ettorre G, Paoletti F, D'Avino A, Ciccarelli N, Sidella L, Murri R, Fortuna S, Vullo V, Cauda R, De Luca A, Di Giambenedetto S. Fabbiani M, et al. Among authors: cauda r. Scand J Infect Dis. 2014 Jan;46(1):34-45. doi: 10.3109/00365548.2013.840920. Epub 2013 Oct 28. Scand J Infect Dis. 2014. PMID: 24161018 Clinical Trial.
538 results